Dualsystems Biotech is driving its business activities towards new technologies and builds up new strengths in the field of protein interaction discovery.

Dualsystems Biotech AG Press Release For immediate distribution

Dualsystems Biotech sells its yeast two-hybrid (Y2H) activities to Hybrigenics
Dualsystems is driving its business activities towards new technologies and builds up new strengths in the
field of protein interaction discovery

Zurich/Schlieren, Switzerland, 1 July 2013 – Dualsystems Biotech, a privately held biotech company based in Schlieren,
Switzerland, announces the sale of its yeast two-hybrid (Y2H) activities to Hybrigenics Services. The financial terms of
this transaction are not disclosed.

Based on the recently closed licensing agreement with the ETH Zurich on an innovative mass spectrometry-based
ligand-receptor capture technology for the identification of extracellular targets Dualsystems has already indicated its
new direction on the target discovery market. The sale of its yeast two-hybrid activities is a further step in that direction
and emphasizes Dualsystems’ commitment to develop and offer to its customers new and highly innovative
technologies in the field of protein interaction discovery in mammalian cells.

Dualsystems Biotech sells its yeast two-hybrid (Y2H) activities to Hybrigenics 73 K